UroGen Pharma (URGN) Total Current Liabilities (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Total Current Liabilities data on file, last reported at $50.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 20.56% year-over-year to $50.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (up 20.56% YoY) and the FY2025 annual result came in at $46.4 million, up 1.02% from the prior year.
• Total Current Liabilities rose to $50.6 million in Q1 2026, from $46.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $50.6 million in Q1 2026 to a low of $18.0 million in Q2 2022.
• A 5-year average of $32.8 million and a median of $31.2 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities fell 5.33% — and 2025, when it jumped 59.45%.
• Tracing URGN's Total Current Liabilities over 5 years: stood at $23.9 million in 2022, then jumped by 30.51% to $31.2 million in 2023, then surged by 47.22% to $45.9 million in 2024, then advanced by 1.02% to $46.4 million in 2025, then rose by 9.08% to $50.6 million in 2026.
• The last three Total Current Liabilities figures came in at $50.6 million (Q1 2026), $46.4 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.